Feature Micromedic seeking diagnostic partners on multiple fronts By Len Zehr With approvals in Europe and Israel for its CellDetect non-invasive test for recurrence of bladder cancer, Micromedic Technologies (TASE:MCTC) is seeking FDA approval for a pivotal trial expected to begin in... October 25, 2016